Heather McCann Selected Research

Parkinson Disease (Parkinson's Disease)

1/2023	Effects of STN/SNr deep brain stimulation in a case of progressive supranuclear palsy with a Parkinson disease phenotype.
2/2016	Neuropathology of α-synuclein propagation and braak hypothesis.
1/2014	α-Synucleinopathy phenotypes.
2/2011	Lipid pathway alterations in Parkinson's disease primary visual cortex.
10/2009	Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression.
7/2009	No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism.
1/2008	Human-based studies on alpha-synuclein deposition and relationship to Parkinson's disease symptoms.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Heather McCann Research Topics

Disease

7	Parkinson Disease (Parkinson's Disease) 01/2023 - 01/2008
6	Alzheimer Disease (Alzheimer's Disease) 11/2015 - 04/2002
4	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2023 - 10/2015
3	Frontotemporal Dementia (Semantic Dementia) 01/2019 - 07/2013
3	Multiple System Atrophy 01/2014 - 02/2006
2	Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome) 01/2023 - 10/2009
2	Dementia (Dementias) 01/2014 - 03/2002
2	Parkinsonian Disorders (Parkinsonism) 10/2009 - 07/2009
1	Proteostasis Deficiencies 11/2023
1	Amyloid Plaque 01/2023
1	Gliosis 01/2023
1	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2022
1	Frontotemporal Lobar Degeneration (Degeneration, Frontotemporal Lobar) 01/2019
1	Substance-Related Disorders (Drug Abuse) 08/2018
1	Neuroinflammatory Diseases 11/2015
1	Myoclonic dystonia 10/2015
1	Neuroaxonal Dystrophies (Neuroaxonal Dystrophy, Late Infantile) 01/2014
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2014
1	Synucleinopathies 01/2014
1	Corticobasal Degeneration 10/2009
1	Inflammation (Inflammations) 07/2009
1	Pain (Aches) 05/2006
1	Congenital Abnormalities (Deformity) 05/2006

Drug/Important Bio-Agent (IBA)

3	DNA-Binding Proteins (DNA Binding Protein)IBA 01/2022 - 10/2015
3	SynucleinsIBA 02/2016 - 01/2014
3	Proteins (Proteins, Gene)FDA Link 10/2009 - 03/2002
2	Biomarkers (Surrogate Marker)IBA 01/2019 - 11/2015
2	Amyloid (Amyloid Fibrils)IBA 11/2015 - 07/2009
2	CholesterolIBA 02/2011 - 08/2010
2	Amyloid beta-PeptidesIBA 08/2010 - 01/2010
2	Presenilin-1IBA 07/2009 - 04/2002
2	alpha-SynucleinIBA 01/2008 - 02/2006
1	CopperIBA 01/2023
1	Riluzole FDA LinkGeneric 01/2023
1	CuATSMIBA 01/2023
1	ProgranulinsIBA 01/2019
1	antiarrhythmic peptide (AAP)IBA 08/2018
1	Muramidase (Lysozyme)IBA 11/2015
1	AntibodiesIBA 07/2013
1	Glycerophospholipids (Phosphoglycerides)IBA 02/2011
1	LipidsIBA 02/2011
1	OxysterolsIBA 02/2011
1	SphingolipidsIBA 02/2011
1	ATP-Binding Cassette Transporters (ABC Transporters)IBA 01/2010
1	ParaffinIBA 10/2009
1	Formaldehyde (Formol)FDA Link 10/2009
1	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 07/2009
1	Presenilin-2IBA 07/2009
1	Advanced Glycation End ProductsIBA 04/2002

Therapy/Procedure

1	Therapeutics 11/2023
1	Deep Brain Stimulation 01/2023
1	Transplantation 07/2009
1	Osteotomy 05/2006